British Patient Capital has invested in Proximie, the global health technology platform digitising operating rooms around the world, as part of a $80 million Series C round.
The $12.5 million investment has been made via Future Fund: Breakthrough, British Patient Capital’s £375 million programme where it co-invests with private sector investors in innovative, R&D-intensive UK companies. The round was led by Advent Life Sciences and is British Patient Capital’s fourth life sciences deal following previous investments in Microbiotica, Epsilogen and Quell Therapeutics.
